ADAM10 and early-onset autosomal dominant Alzheimer disease: Several compounds modulating the expression and activity of ADAM10 have been investigated for their therapeutic potential in clinical trials [84], including the use of Rapamycin for the inhibition of ADAM10 activity in Alzheimer disease [85].